illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Ryvu Therapeutics
Company logo

Ryvu Therapeutics | Sustainability Performance

https://ryvu.com

This firm is involved in biotechnology research and development, focusing on innovative therapies aimed at treating cancer and other serious diseases. Its work emphasizes advancing novel treatment options.

2007

Poland

201 - 500 employees

Biotechnology

$10M - 25M in revenue

Not profitable

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#4497
Overallⓘ
#34
in Polandⓘ
#88
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

201 out of 244

Overview

View similiar companies


Company logo
Selvita

Poland, Health Care, Biotechnology


Company logo
BioKangtai

China, Health Care, Biotechnology


Company logo
Arcturus Therapeutics

United States, Health Care, Biotechnology

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.


    Available in
    Scale package

    Access
  • Email

  • Email